Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incidence of low volume metastases according to Silva pattern in cervical adenocarcinoma undergoing sentinel lymph node biopsy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

The Keystone Flap for Vulvar Reconstruction: A Case Series and BODY-Q Evaluation.

Plastic and reconstructive surgery. Global open·2026
Same author

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026
Same author

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Lancet (London, England)·2026
Same author

Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Single-port robotic surgery in gynecologic oncology: feasibility and safety after 1 year of implementation.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Related Experiment Video

Updated: Jul 12, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Chemo-conization in early cervical cancer.

Fabio Landoni1, Gabriella Parma, Michele Peiretti

  • 1Division of Gynecology European Institute of Oncology, Milan, Italy. Fabio.Landoni@ieo.it

Gynecologic Oncology
|August 31, 2007
PubMed
Summary

Chemo-conization is a safe and feasible fertility-sparing treatment for early-stage cervical cancer in young women. This approach demonstrated no recurrences and successful pregnancies in a small cohort.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Related Experiment Videos

Last Updated: Jul 12, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Area of Science:

  • Gynecology
  • Oncology
  • Reproductive Medicine

Background:

  • Cervical cancer treatment traditionally involves hysterectomy, leading to infertility.
  • Young patients desiring fertility preservation require alternative treatment strategies.

Purpose of the Study:

  • To evaluate the safety and feasibility of chemo-conization for early-stage cervical cancer in young women.
  • To assess oncologic and obstetrical outcomes in patients undergoing fertility-sparing treatment.

Main Methods:

  • Eleven patients with early-stage cervical tumors (<3 cm) and fertility preservation goals were included.
  • Treatment involved neoadjuvant chemotherapy followed by conization and pelvic lymphadenectomy.
  • Obstetrical and oncologic outcomes were monitored post-treatment.

Main Results:

  • The study included 11 patients (mean age 32) with FIGO Stage IB1 (8 cases) or IA2 (3 cases) cervical cancer.
  • Histological types included squamous cell carcinoma (5) and adenocarcinoma (6).
  • No recurrences were observed after a median follow-up of 20 months; three pregnancies occurred.

Conclusions:

  • Chemo-conization is a feasible fertility-sparing option for selected young patients with early-stage cervical cancer.
  • This conservative approach can achieve oncologic control while preserving fertility.
  • Further research with larger cohorts is warranted to confirm these findings.